The Trump administration’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving non-medical marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29, 2026, before an administrative law judge and concluded no later than July 15; only opponents of rescheduling were selected to participate. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs. A federal appeals court in September 2026 rejected efforts to stay the process. Resolution of the broader rulemaking now depends on the ALJ recommendation, any final agency rule, and ongoing litigation, with no firm timeline for completion beyond the hearing record.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật$810,189 KL.
Sep 30, 2026
September 30
2%
December 31
16%
$810,189 KL.
September 30
$679 KL.
2%
December 31
$199,939 KL.
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving non-medical marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29, 2026, before an administrative law judge and concluded no later than July 15; only opponents of rescheduling were selected to participate. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs. A federal appeals court in September 2026 rejected efforts to stay the process. Resolution of the broader rulemaking now depends on the ALJ recommendation, any final agency rule, and ongoing litigation, with no firm timeline for completion beyond the hearing record.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Thị trường mở: Jul 31, 2026, 5:46 PM ET
Khối lượng
$810,189Ngày kết thúc
Jan 1, 2027Thị trường mở
Jul 31, 2026, 5:46 PM ETNgười giải quyết
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving non-medical marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29, 2026, before an administrative law judge and concluded no later than July 15; only opponents of rescheduling were selected to participate. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs. A federal appeals court in September 2026 rejected efforts to stay the process. Resolution of the broader rulemaking now depends on the ALJ recommendation, any final agency rule, and ongoing litigation, with no firm timeline for completion beyond the hearing record.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Khối lượng
$810,189Ngày kết thúc
Jan 1, 2027Thị trường mở
Jul 31, 2026, 5:46 PM ETNgười giải quyết
0x65070BE91...The Trump administration’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving non-medical marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29, 2026, before an administrative law judge and concluded no later than July 15; only opponents of rescheduling were selected to participate. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs. A federal appeals court in September 2026 rejected efforts to stay the process. Resolution of the broader rulemaking now depends on the ALJ recommendation, any final agency rule, and ongoing litigation, with no firm timeline for completion beyond the hearing record.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp